EUVIMEDEUVIMED entdecken
Crossref

Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy

Emily Harris

JAMA · 2024

DOI: 10.1001/jama.2023.26113 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, 2024. Verfasst von Emily Harris. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, CRISPR-Cas Systems, Gene Editing, Genetic Therapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The US Food and Drug Administration (FDA) recently greenlit 2 cell-based gene treatments for sickle cell anemia, including the first therapy involving the genome editing technology known as CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats–CRISPER-associated protein 9).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellCRISPR-Cas SystemsGene EditingGenetic TherapyHumansClustered Regularly Interspaced Short Palindromic Repeats

Zitieren

APA

Harris, E. (2024). Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy. JAMA. https://doi.org/10.1001/jama.2023.26113

Vancouver

Harris E. Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy. JAMA. 2024. doi:10.1001/jama.2023.26113

BibTeX
@article{Harris2024,
  author = {Harris, Emily},
  title = {Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy},
  journal = {JAMA},
  year = {2024},
  doi = {10.1001/jama.2023.26113}
}
Kostenlos starten →